Article Text
Statistics from Altmetric.com
The decision by the UK Medicines and Health Care products Regulatory Agency (MHRA) to impose severe restrictions on the prescribing of valproate for men under 55 years1 2 seems to be unwise, based on tenuous scientific underpinnings, and potentially dangerous for boys and men with epilepsy. In the UK, from January 2024, ‘valproate must not be started in new patients, male or female, younger than 55 years unless two specialists independently consider and document that there is no other effective or tolerated treatment, or there are compelling reasons that the reproductive risks do not apply’.1
Undoubtedly, valproate use in women poses major hazards to the unborn child, including increased risks of major congenital malformations3 and neurodevelopmental disorders.4–6 Despite a decline in valproate prescribing in women, many pregnancies continue to be exposed to valproate.7 This justifies efforts to improve compliance with existing restrictions,8 even though the wisdom of requiring an independent intervention of two specialists has been questioned.9
Should similar restrictions on valproate prescribing also apply to men? Case reports indicate that valproate can affect sperm count, motility and morphology.10 However, male infertility is considered to be rare11 and reversible after treatment discontinuation or dose reduction, at least in some cases.10 Valproate can cause testicular toxicity …
Footnotes
Contributors SFB and EP contributed equally.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests SFB receives research funding from NHMRC and has received unrestricted educational grants from UCB Pharma, Eisai, SEER, Chiesi and Liva Nova. He has received consultancy fees for Praxis Precision Medicines and receives remuneration as chief medical officer for the Epilepsy Foundation of Victoria. EP received speaker’s or consultancy fees from Angelini, Eisai, Janssen, PMI Life Sciences, Sanofi group of companies, UCB Pharma, Shackelford Pharma, Sintetica, SKL Life Science, Takeda, UCB Pharma and Xenon Pharma, and royalties from Wiley, Elsevier and Wolters Kluwers. He is also on the board of EURAP-International Registry of Antiepileptic Drugs and Pregnancy, a non-profit organisation which received financial support from Accord, Angelini, Bial, EcuPharma, Eisai, Glenmark, GW Pharma, GlaxoSmithKline, Sanofi, SF Group, Teva, UCB and Zentiva.
Provenance and peer review Commissioned; externally peer reviewed by Tony Marson, Liverpool, UK.
Read the full text or download the PDF:
Other content recommended for you
- Paternal exposure to antiseizure medications and offspring outcomes: a systematic review
- Management of epilepsy during pregnancy and lactation
- Preconception counselling in women with epilepsy
- Paternal exposure to antiseizure medications and offspring outcomes
- Weighing the risks of valproate in women who could become pregnant
- Valproate and childbearing potential: new regulations
- Epilepsies in children, young people, and adults: summary of updated NICE guidance
- Paternal exposure to antiepileptic drugs and offspring outcomes: a nationwide population-based cohort study in Sweden
- Valproate: Men planning a family should seek advice in light of neurodevelopmental disorders risk in children, says regulator
- Epilepsy and pregnancy: identifying risks